Search

Displaying results 3611 - 3620 of 10000 in total
  1. Drug

    Dabigatran etexilate

    go.drugbank.com/drugs/DB06695
    ApprovedInvestigational

    Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor [dabigatran]. … [A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated.

  2. Drug

    Repaglinide

    go.drugbank.com/drugs/DB00912
    ApprovedInvestigational

    Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. … Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose.

  3. Drug

    Palovarotene

    go.drugbank.com/drugs/DB05467
    Approved

    [L39990,L40020] It has been granted rare pediatric disease and breakthrough therapy designations from the US FDA, although a previously submitted NDA was withdrawn in August 2021 pending the resubmission … [A244920] The ossification occurring as a result of FOP is insidious and cumulative and is provoked during flare-ups or in response to injury.

  4. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive … Deutivacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) potentiator.

  5. Drug

    Prucalopride

    go.drugbank.com/drugs/DB06480
    ApprovedInvestigational

    [A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880] … Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties.

  6. Drug

    Tocofibrate

    go.drugbank.com/drugs/DB19752
    Experimental

    The usage of the INN stem '-fibrate' in the name indicates that Tocofibrate is a clofibrate derivative, peroxisome proliferator activated receptor-a (PPAR-a) agonist. … Tocofibrate is a small molecule drug.

  7. Drug

    Pirifibrate

    go.drugbank.com/drugs/DB20620
    Experimental

    The usage of the INN stem '-fibrate' in the name indicates that Pirifibrate is a clofibrate derivative, peroxisome proliferator activated receptor-a (PPAR-a) agonist. … Pirifibrate is a small molecule drug.

  8. Drug

    Salafibrate

    go.drugbank.com/drugs/DB20767
    Experimental

    The usage of the INN stem '-fibrate' in the name indicates that Salafibrate is a clofibrate derivative, peroxisome proliferator activated receptor-a (PPAR-a) agonist. … Salafibrate is a small molecule drug.

  9. Drug

    Nicofibrate

    go.drugbank.com/drugs/DB19916
    Experimental

    The usage of the INN stem '-fibrate' in the name indicates that Nicofibrate is a clofibrate derivative, peroxisome proliferator activated receptor-a (PPAR-a) agonist. … Nicofibrate is a small molecule drug.

  10. Drug

    Dulofibrate

    go.drugbank.com/drugs/DB20032
    Experimental

    The usage of the INN stem '-fibrate' in the name indicates that Dulofibrate is a clofibrate derivative, peroxisome proliferator activated receptor-a (PPAR-a) agonist. … Dulofibrate is a small molecule drug.